>50% relative reduction in ARR vs teriflunomide (P<0.001), with nearly 9 out of 10 patients achieving NEDA-3 at year 2 (post hoc analysis).2,3
‡Self-administered at-home B-cell therapy.1
KESIMPTA™
Indication: KESIMPTA™ is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (MS).2
ARR, annual relapse rate; CDW, confirmed disability worsening; Gd+, gadolinium-enhancing; RMS, relapsing multiple sclerosis; NEDA, no evidence of disease activity.
KESIMPTA™ API
KESIMPTA™ API
References
Hauser SL, Bar-Or A, Cohen JA, et al. for the ASCLEPIOS I and ASCLEPIOS II trial groups.
Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med. 2020;383(6):546-557.Kesimpta insert leaflet, Novartis Pharma AG, Switzerland.
Hauser SL, Bar-Or A, Cohen JA, et al. B-cell depletion and efficacy outcomes with ofatumumab: subgroup analysis from the pooled phase 3 ASCLEPIOS I and II trials. Poster P7.1-013. Presented at:
American Academy of Neurology Annual Meeting; May 4-10, 2019; Philadelphia, PA.